3rd Edition Track Finals: BSim2 poster
1
Financial Highlights Promotor team Catarina Maia, MBA Target Market A suite of computational screening workflows Partners Center for Neuroscience and Cell Biology University of Coimbra Maria João Saraiva, PhD University of Porto Ernesto Freire, PhD Johns Hopkins University Sheena Radford, PhD University of Leeds Our Approach The Problem - Drug R&D: high costs, long times - Dry out of the drug discovery pipelines - Ageing of World population - Increasing incidence of neurodegenerative diseases Our Solutions Products — First in pipeline New drug candidates against transthyretin-related diseases: - Familial Amyloid Polyneuropathy (FAP) - Familial Amyloid Cardiomyopathy (FAC) - Senile Systemic Amyloidosis (SSA) Our Advantages - Higher specificity / efficacy - Lower toxicity and side-effects - Lower risks and costs Surfing chemical space to hit biological targets Anti-FAP products up to US$1.2 billion/year * Estimated costs and revenues in thousands of US Dollars Our Business Model Licensing and joint-venture agreements with strategic partners in Pharma and Biotech industries Secured and required funds in thousands of US Dollars (2012-2016) Competition *Based on the number of FAP patients and the asking price for VYNDAQEL ® Investment sought: US$2.8M NPV: US$6.9M Payback: 2.1 years Compound Company Discovery in vitro PoC in vivo PoC Preclinical Phase I Phase II Phase III Market VYNDAQEL ® Small molecule Pfizer SOM0226 Repositioned SOM Biotech mds84 Small molecule Pentraxin Therapeutics ISIS-TTR RX Antisense ISIS Pharmaceuticals ALN-TTR 02 siRNA Alnylam Pharmaceuticals asking price of US$150/patient/year + Milestones AT-06,09,12 Small molecule BSIM 2 Carlos J. V. Simões, PharmD Rui M. M. Brito, PhD
-
Upload
building-global-innovators -
Category
Documents
-
view
559 -
download
0
description
Transcript of 3rd Edition Track Finals: BSim2 poster
Financial Highlights
Promotor team
Catarina Maia, MBA
Target Market
A suite of computationalscreening workflows
Partners
Center for Neuroscience andCell Biology
University of Coimbra
Maria João Saraiva, PhDUniversity of Porto
Ernesto Freire, PhDJohns Hopkins University
Sheena Radford, PhDUniversity of Leeds
Our ApproachThe Problem- Drug R&D: high costs, long times
- Dry out of the drug discovery pipelines
- Ageing of World population
- Increasing incidence of neurodegenerative diseases
Our SolutionsProducts — First in pipeline
New drug candidates againsttransthyretin-related diseases:
- Familial Amyloid Polyneuropathy (FAP)
- Familial Amyloid Cardiomyopathy (FAC)
- Senile Systemic Amyloidosis (SSA)
Our Advantages- Higher specificity / efficacy- Lower toxicity and side-effects- Lower risks and costs
Surfing chemical space to hit biological targets
Anti-FAP products
up to
US$1.2 billion/year*
Estimated costs and revenuesin thousands of US Dollars
Our Business ModelLicensing and joint-venture agreementswith strategic partners in Pharma and Biotech industries
Secured and required fundsin thousands of US Dollars
(2012-2016)
Competition
*Based on the number of FAP patients and the asking price for VYNDAQEL®
Investment sought: US$2.8M NPV: US$6.9M Payback: 2.1 years
Compound Company Discovery in vitroPoC
in vivoPoC
Preclinical PhaseI
PhaseII
PhaseIII
Market
VYNDAQEL®
Small moleculePfizer
SOM0226Repositioned SOM Biotech
mds84Small molecule
PentraxinTherapeutics
ISIS-TTRRXAntisense
ISISPharmaceuticals
ALN-TTR02
siRNAAlnylam
Pharmaceuticals
asking price of US$150/patient/year
+ Milestones
AT-06,09,12Small molecule
BSIM2
Carlos J. V. Simões, PharmD
Rui M. M. Brito, PhD
